JP2016512214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512214A5 JP2016512214A5 JP2015562176A JP2015562176A JP2016512214A5 JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5 JP 2015562176 A JP2015562176 A JP 2015562176A JP 2015562176 A JP2015562176 A JP 2015562176A JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- epitope
- amino acid
- tfpi
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789274P | 2013-03-15 | 2013-03-15 | |
| EP13159515 | 2013-03-15 | ||
| US61/789,274 | 2013-03-15 | ||
| EP13159515.9 | 2013-03-15 | ||
| PCT/EP2014/055055 WO2014140240A1 (en) | 2013-03-15 | 2014-03-14 | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512214A JP2016512214A (ja) | 2016-04-25 |
| JP2016512214A5 true JP2016512214A5 (enExample) | 2017-04-20 |
| JP6586016B2 JP6586016B2 (ja) | 2019-10-02 |
Family
ID=47877935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562176A Active JP6586016B2 (ja) | 2013-03-15 | 2014-03-14 | 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9896513B2 (enExample) |
| EP (1) | EP2970499B1 (enExample) |
| JP (1) | JP6586016B2 (enExample) |
| CN (1) | CN105209497B (enExample) |
| ES (1) | ES2926773T3 (enExample) |
| WO (1) | WO2014140240A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2015007880A1 (en) * | 2013-07-19 | 2015-01-22 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| EP3337827B1 (en) | 2015-08-19 | 2026-07-08 | Pfizer Inc. | Tissue factor pathway inhibitor antibodies and uses thereof |
| CN106554420A (zh) * | 2015-09-30 | 2017-04-05 | 上海众合医药科技股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| US10794896B2 (en) * | 2016-01-29 | 2020-10-06 | Sony Corporation | Blood coagulation system examination module, blood coagulation system examination system, blood coagulation system examination method, and determination method of parameter for blood coagulation system examination module |
| MA50677A (fr) * | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| AU2018205401B2 (en) | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| EP3863664A1 (en) | 2018-10-11 | 2021-08-18 | Pfizer Inc. | Dosage regimen for tfpi antagonists |
| JP2022506696A (ja) * | 2018-11-07 | 2022-01-17 | ボーダックス バイオ インコーポレーテッド | Ｉｖメロキシカムにより血小板機能異常症の対象を治療する方法 |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| CN110156890B (zh) * | 2019-04-09 | 2021-02-02 | 苏州大学 | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| ATE300519T1 (de) | 1989-04-19 | 2005-08-15 | Enzon Inc | Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0539975A1 (en) | 1991-10-31 | 1993-05-05 | Teijin Limited | Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2292273A3 (en) | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| BRPI0611570A2 (pt) | 2005-06-15 | 2011-02-22 | Novo Nordisk Healthcare Ag | métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto |
| WO2010072687A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| TW201212938A (en) * | 2010-06-30 | 2012-04-01 | Novo Nordisk As | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| ES2722824T3 (es) | 2011-04-01 | 2019-08-19 | Bayer Healthcare Llc | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) |
-
2014
- 2014-03-14 US US14/775,108 patent/US9896513B2/en active Active
- 2014-03-14 JP JP2015562176A patent/JP6586016B2/ja active Active
- 2014-03-14 EP EP14710541.5A patent/EP2970499B1/en active Active
- 2014-03-14 ES ES14710541T patent/ES2926773T3/es active Active
- 2014-03-14 WO PCT/EP2014/055055 patent/WO2014140240A1/en not_active Ceased
- 2014-03-14 CN CN201480027370.2A patent/CN105209497B/zh active Active
-
2018
- 2018-01-09 US US15/866,007 patent/US10717784B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2017529097A5 (enExample) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| JP2017532313A5 (enExample) | ||
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
| JP2017113019A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| IL299282B1 (en) | Enhanced variable complexes of immunoglobulins | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2017508475A5 (enExample) |